NASDAQ
23.96USD
+0.93 (+4.04%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3B
P/E
—
EPS
—
Beta
-0.67
52W range
3.76-31.35
Day range
23.23–24.04
Open
23.52
Prev close
23.03
Volume
587.2K
Avg volume
1.2M
Dividend
0.00
IPO
2024-06-28
https://www.fool.com/coverage/filings/2026/05/24/this-biotech-stock-is-up-355-one-fund-added-a-usd169-million-position-last-quarter/ · 5/24/2026+0.60
https://www.fool.com/coverage/filings/2026/05/10/act-capital-loads-up-174k-alms-shares-worth-44-million/ · 5/10/2026+0.60
https://www.defenseworld.net/2026/02/28/axq-capital-lp-invests-78000-in-alumis-inc-alms.html · 2/28/2026+0.20
https://247wallst.com/investing/2026/01/19/huge-insider-buying-now-at-this-insurance-giant-and-2-biotechs/ · 1/19/2026+0.80
https://www.fool.com/coverage/filings/2026/01/17/an-almus-alms-insider-bought-588-000-shares-for-usd10-0-million/ · 1/17/2026+1.00
https://www.globenewswire.com/news-release/2026/01/08/3215030/0/en/Alumis-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html · 1/8/2026+0.60
https://www.fool.com/coverage/stock-market-today/2026/01/06/stock-market-today-jan-6-alumis-shares-surge-on-positive-phase-3-psoriasis-data-for-envudeucitinib/ · 1/6/2026+1.00
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
